Y 90 CHIMERIC T84 66 ANTI CEA ANTIBODY IN ADVANCE CEA PRODUCING MALIG

医生摘要：本试验将确定Y-90嵌合T84.66的最大耐受量和相关毒性，并评估其在腹部癌病患者中应用的可行性。这项试验还将评估辐射剂量学、抗体的生物分布和清除，并将开始评估其抗肿瘤效果。医生资格摘要：组织学诊断为CEA(癌胚抗原)产生肿瘤的癌症；大多数癌症仅限于腹膜腔内，对先前的常规治疗无反应；必须有可测量或可评估的疾病；既往无丝裂霉素C或硝酸甘油化疗；既往没有腹部或盆腔放射治疗或放射治疗超过骨髓的50%；肝脏受累超过25%的患者不符合条件；既往免疫治疗或化疗允许；年龄大于或等于18岁；必须满足或超过60%的Karnofsky功能状态(患者偶尔需要帮助，但能够照顾到他们自己的大部分需要)。

Physician Abstract: This trial will determine the maximum tolerated dose, the associated toxicities and evaluate the feasibility of delivering intraperitoneally administered Y-90 chimeric T84.66 for patients with abdominal carcinomatosis. This trial will also evaluate radiation dosimetry, antibody biodistribution and clearance and will begin to evaluate its anti-tumor effects. Physician Eligibility Summary: Histological diagnosis of cancer with CEA (Carcinoembryonic Antigen) producing tumors; Cancer of which the majority is confined to the peritoneal cavity and unresponsive to previous conventional treatment; Must have measurable or evaluable disease; No prior chemotherapy with Mitomycin-C or Nitrosureas; No prior abdomen or pelvic radiation therapy or radiation therapy to greater than 50% of bone marrow; Patients with greater than 25% liver involvement are ineligible; Prior immunotherapy or chemotherapy allowed; Age greater than or equal to 18 years; Must meet or exceed a Karnofsky Performance Status of 60% (Patient requires occasional assistance but is able to care for most of their own needs).